Premium
Positron emission tomography imaging in nonsmall‐cell lung cancer
Author(s) -
Erasmus Jeremy J.,
Macapinlac Homer A.,
Swisher Stephen G.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23051
Subject(s) - medicine , positron emission tomography , nuclear medicine , lung cancer , cancer , positron emission tomography computed tomography , tomography , preclinical imaging , radiology , brain positron emission tomography , pathology , in vivo , microbiology and biotechnology , biology
Positron emission tomography (PET) using 18F‐2‐deoxy‐D‐glucose, a D‐glucose analog labeled with fluorine‐18, complements conventional radiologic assessment in the evaluation of patients with nonsmall‐cell lung cancer (NSCLC). PET is being routinely used to improve the detection of nodal and extrathoracic metastases. PET is also currently being evaluated in the assessment of prognosis and therapeutic response and by potentially allowing an earlier assessment of response may prove invaluable in the oncologic management of patients. The article discusses the diagnosis, staging, and assessment of treatment response and prognosis with an emphasis on the appropriate clinical use of PET in management. Cancer 2007. © 2007 American Cancer Society.